Garratty G

Language: English
References: 17
Page: 107-111
PDF size: 122.43 Kb.

ABSTRACT

If all red blood cells (RBCs) (and most or all RBCs of a phenotyped red cell panel) are incompatible when tested with a patient’s serum/plasma, the results may be due to autoantibody(ies) or alloantibody(ies). In a patient who has not been transfused recently, the differentiation is easy by looking at the result with autologous RBCs. If autologous RBCs are not reacting, then the incompatibilities are due to alloantibody(ies). If the autologous RBCs are incompatible, then an autoantibody alone or an autoantibody plus alloantibody may be present. If the patient has been transfused recently, then the results with autologous RBCs may not have much value and further procedures (e.g., separating transfused “older” RBCs from autologous “younger” RBCs) may be necessary. The autoantibody or alloantibody may react optimally at cold (0-5 °C) or warm (37 °C) temperatures. Table I shows some of the specificities that may be involved when all, or most, RBCs tested are reacting.

REFERENCES

1. Petz LD, Garratty G. Immune hemolytic anemias. Second edition. Philadelphia: Churchill Livingstone; 2004.

2. Branch DR, Petz LD. Detecting alloantibodies in patients with autoantibodies. Transfusion 1999;39:6-10.

3. Engelfriet CP, Reesink HW. The detection of alloanti-bodies against red cells in patients with warm-type autoimmune haemolytic anaemia. Vox Sang 2000;78: 200-7.

4. Garratty G, Petz LD. Approaches to selecting blood for transfusion to patients with autoimmune hemolytic anemia. Transfusion 2000;42:1390-2.

5. Leger RM, Garratty G. Evaluation of methods for detecting alloantibodies underlying warm auto-antibodies. Transfusion 1999;39:11-16.

6. Brecher M, ed. Techncial manual. 15th ed. Bethesda, MD: American Association of Blood Banks; 2005.

7. Oyen R, Angeles ML. A simple screening method to evaluate the presence of alloantibodies with concomitant warm autoantibodies. Immunohema-tology 1995;11:85-7.

8. Leger RM, Garratty G. Weakening or loss of antibody reactivity after prewarm technique. Transfusion 2003;23:1611-14.

9. Reid ME, Lomas-Francis C. The blood group antigen facts book. Second edition. New York: Academic Press, 2004.

10. Garratty G. Predicting the clinical significance of red cell antibodies with in vitro cellular assays. Transfus Med Rev 1990;IV:297-312.

11. Arndt PA, Garratty G. A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies. Transfusion 2004;44:1273-81.

12. Leger RM. In vitro cellular assays and other approaches used to predict the clinical significance of red cell alloantibodies: a review. Immunohematology 2002;18:65-70.

13. Nance ST, Arndt PA. Review: what to dowhen all RBCs are incompatible – serologic aspects. Immuno-hematology 2004;20:147-60.

14. International Committee for Standardization in Haema-tology. Recommended method for radioisotope red-cell survival studies. Br J Haematol 1980;45:659-55.

15. Engelfriet CP, Ouwehand WH. ADCC and other cellular bioassays for predicting the clinical signifi-cance of red cell alloantibodies. Baillieres Clin Haematol 1990;3:321-37.

16. Hadley A, Wilkes A, Poole J, Arndt P, Garratty G. A chemiluminescence test for predicting the outcome of transfusing incompatible blood. Transfus Med 1999;9:337-42.

17. Leger R, Arndt P, Co A, O’Brien L, Garratty G. Clinical significance of an anti-Dib assessed by flow cytometry.